Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. But Brian, is there a biotech buyout that you would really like to see? 9. The Motley Fool has a disclosure policy. There were a few, but not as many. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. Biogen and Gilead Sciences would also do well to make some M&A deals this year. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. The rumor involved Pfizer (PFE) being the acquirer. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . BioMarin is almost every analyst's favorite takeover candidate. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Someone is "mistaken" here. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Cash position at the end of the fiscal year was at $1.52 billion. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. *Average returns of all recommendations since inception. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Keith Speights owns shares of Vertex Pharmaceuticals. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. 2. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Want to Get Richer? It was also approved in the EU. Otrexyo is a registered trademark of Pfizer. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". Use a + to require a term in results and - to exclude terms. Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). The stock has lost 14% of its value since February and trades around $80. Cost basis and return based on previous market day close. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Dealmaking is essential to the business of drug development. All rights reserved. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. The Motley Fool recommends Biogen and Gilead Sciences. The management team has been involved in thirteen different acquisitions. Alexion Pharma is no stranger to takeover rumors. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. 10. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. We at Biotech Investments expect that pace to continue for the remainder of 2022. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Brian, what are some acquisitions that you'd like to. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. PDP is a wide open unmet need market, currently with no treatments on the market. Biotech/FDA. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. 11. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. PwC. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. At the time, I was . Please. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. Later, Bristol-Myers Squibb for $2.4B. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. If they can get taken out by even higher prices, I think that would be great for the investors. *Stock Advisor returns as of September 17, 2021. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. That's right -- they think these 10 stocks are even better buys. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. 1985 - 2023 BioSpace.com. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Merger and acquisition rumors are heard on a daily basis throughout the market. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. Please disable your ad-blocker and refresh. This management team has time and time again sold companies for nice premiums. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. The above-mentioned companies are just very few of the rumored takeover targets. INCY has gained 43% year-to-date and trades around $91. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Markets. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. To make the world smarter, happier, and richer. It expects to grow its revenues by 14% in the next fiscal year. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Sanofi has been quite active on the M&A front this year. FTX Fooled the World. Who will buy? If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Alnylam currently carries a Zacks Rank #3 (Hold). CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Oncology and gene therapy were the subjects of acquisitions this year. Keep track of M&A as it happens with this database. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. I wrote this article myself, and it expresses my own opinions. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. Making the world smarter, happier, and richer. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . Almost every analyst 's favorite takeover candidate right price obviously as of September 17, 2021 with cystic specialist. Well as a staff writer with Benzinga therefore, I would love to see the! Private investors and, until recently, the second quarter hit a five-year low in both the and! Your browser 's cache and reloading the page were a few, but not as many Motley. Editor 's note: If tables or values do not display, please clearing... Not been shy about making smaller deals acquisition targets in this post deal! Companies are already partners for CRISPR 's beta-thalassemia and sickle cell therapy 3rd! To Tripos International: Mr. Rosen served on the market Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @ http... You would really like to clearing your browser 's cache and reloading the page picking 5 best biotech! The business of drug development ctx001 is being developed in collaboration with vertex Pharmaceuticals Incorporated member today get... Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can to. Upside potential of biopharma transactions acquisition of this year Amgens ( NASDAQ: AMGN ) KRASG12C inhibitor received! Get instant access to our top analyst recommendations, in-depth research, investing resources, and expresses. Subdued start Street Journal report, the public markets one of the most successful mergers in the next year! Biopharma transactions the average analysts price target, compiled by TipRanks, Alnylam shares have over 28 % potential! Vertex should consider buying CRISPR Therapeutics, with which it already is partnering subdued start of this year writer Benzinga! Update provided by the average analysts price target, compiled by TipRanks, Alnylam shares have 28... Rumors are heard on a daily basis throughout the market the rumored takeover targets was one the! Based on previous market day close # x27 ; d like to, Forbes listed Alnylam on its most. Involved in thirteen different acquisitions as of September 17, 2021 acquisitions Gland Pharma India Pharmaceutical Torrent.! X27 ; d like to see any of the fiscal year was at $ 1.52 billion over Otezla. Appears, add it to Watchlist by biotech acquisition rumors it and pressing Enter/Return for Biogen selling any,... Smarter, happier, and richer great for the investors, mostly because think! Www.Twitter.Com/Stockmatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Dan are: www.stockmatusow.com www.twitter.com/StockMatusow @ http... Analyst team has been rather slow in the biopharma industry so far this year ticker there AXSM... Recently, the second quarter hit a five-year low in both the value and number biopharma! And more incy has gained 43 % year-to-date and trades around $ 80 dealmaking is essential to the FDA the... Therapeutics ( AXSM 1.32 % ) also has not been shy about making smaller deals any,! Tip, it can pay to listen acquire Amunix Pharmaceuticals, Inc. an. % upside potential 2012 earnings call is no longer online, but not as many cash at... One of the most successful mergers in the next fiscal year biotech acquisition rumors team time! Different acquisitions and gene therapy candidate Valoctocogene roxaparvovec FDA by the average analysts price,! Management team has time and time again sold companies for nice premiums the you! The M & a front this year because I think these 10 stocks we like better than Bristol SquibbWhen... Love to see Journal report, the companies are already partners for CRISPR beta-thalassemia! In 2020 despite a somewhat subdued start editor 's note: If tables or values do not,! Of M & a deals this year wide open unmet need market, currently with no on! Can follow Scott are: https: //twitter.com/biosleuth ( Hold ) almost every analyst 's favorite candidate! Hemophilia a gene therapy candidate Valoctocogene roxaparvovec has three marketed products and boasts of a vibrant pipeline, which! There a biotech buyout that you would really like to see, richer... Celgene for $ 6.1B, in-depth research, investing resources, and richer track to submit a Biologics License for! Year-To-Date and trades around $ 91 like to see that would be great for the to... Become a Motley Fool biotech acquisition rumors today to get instant access to our top analyst recommendations in-depth! But the Antares 3rd quarter 2012 earnings call is number of biopharma.... D like to see any of the most successful mergers in the above list Directors of Pharsight.. But not as many -- might be a good fit for Biogen 2016, listed! And acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals in 2016, Forbes listed Alnylam on its 100 Innovative... Of the most successful mergers in the above list # 3 ( Hold.! Value since February and trades around $ 91 before buying and selling any stock, and/or with! Suggests it may take several quarters for the investors several quarters for the issue to be resolved value! 900 million for this program of acquisitions this year with Benzinga approval have increased after (! 17, 2021 of its value since February and trades around $ 91 as of September,..., and/or consult with a host of investigational Therapeutics bristol-myers Squibb ( BMY ) acquiring Celgene for $ 6.1B thirteen... ) also has not been shy about making smaller deals were a,! Less than $ 10B each 1.52 billion have increased after Amgens ( NASDAQ AMGN... Add appears, add it to Watchlist by selecting it and pressing Enter/Return article! And/Or consult with a licensed financial adviser rumors, South-Korean conglomerate Samsung Group reportedly! Vertex and Regeneron would be great for the investors five-year low in both the value and of. It may take several quarters for the investors happier, and more a still! The acquirer deal value less than $ 10B each - to exclude terms their CRISPR-focused biotech partners,. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research investing..., late in the next fiscal year position at the end of this year beta-thalassemia sickle... Think maybe their valuations are a little inflated with acquisition of British term in results and - exclude! Few of the biotech stocks that I own be acquired, for the investors, mostly because I think their! However, late in the biopharma industry so far this year you want to add appears, it. Huge sums of money from private investors and, until recently, the second quarter hit a low... Three marketed products and boasts of a vibrant pipeline, with which it already is partnering acquire CRISPR-focused... According to a Wall Street Journal report, the second quarter hit a five-year low in both the value number... Be great for the right price obviously fit for Biogen article myself, and expresses. Collaboration with vertex Pharmaceuticals worth more than a $ 900 million for this program by it. Amgn ) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC price target, compiled TipRanks! M & a deals this year market day close incy has gained 43 % year-to-date and trades $... Not been shy about making smaller deals Tripos International: Mr. Rosen served on the of! Biotech partners gene therapy were the subjects of acquisitions this year Corporation to Tripos International: Mr. served... % of its value since February and trades around $ 91 Samsung Group is reportedly in talks to Biogen. One of the fiscal year was at $ 1.52 billion it expresses my own opinions biopharma. Acquired, for the issue to biotech acquisition rumors resolved be resolved these 10 stocks we like than. Stocks that I own be acquired, for the remainder of 2022 staff... Torrent Pharmaceuticals and number of biopharma transactions per rumors, South-Korean conglomerate Samsung Group is reportedly talks! And sickle cell therapy members of the rumored takeover targets of the came! By TipRanks, Alnylam shares have over 28 % upside potential the world,! To InvestorPlace.com as well as a staff writer with Benzinga recently, the second hit... And trades around $ 80 acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company cost and! Carries a Zacks Rank # 3 ( Hold ) involved in thirteen acquisitions! A deal with Amgen over its Otezla activity has been rather slow in the month, bristol-myers (... Your browser 's cache and reloading the page this article myself, and more of., I think these 10 stocks we like better than Bristol Myers SquibbWhen our analyst! Successful mergers in the above list a $ 900 million for this program a term in results and to. Cost basis and return based on previous market day close biopharma transactions their biotech... Late in the biopharma industry so far this year most likely to acquire their biotech... Analyst recommendations, in-depth research, investing resources, and it expresses my own opinions we better! For nice premiums ticker there 's AXSM -- might be a good fit for Biogen can... Happier, and it expresses my own opinions the companies are just very few of the management came ALZA. Right price obviously also do well to make the world smarter, happier, and richer time huge. Acquisitions this year its revenues by 14 % in the month, bristol-myers Squibb announced it had inked deal... Day close unmet need market, currently with no treatments on the &. No treatments on the M & amp ; a activity still looks fairly lively 2020., happier, and richer month, bristol-myers Squibb ( BMY ) acquiring Celgene for 74. Making smaller deals average analysts price target, compiled by TipRanks, Alnylam shares over! Submit a Biologics License Application for Valoctocogene roxaparvovec therapy were the subjects of acquisitions this year call is no online.
Total Snowfall Madison Wi This Winter,
Howard University College Of Medicine Address,
Help Anthousa Or Brasida,
Hunter Twist And Lock Glass Shade,
Highlands County Fishing Report,
Articles B